Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
NCT00240292Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2003
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rosuvastatin in systolic heart failure (HFrEF), sponsored by AstraZeneca. Started Feb 2003; status: completed.
02
Drugs
rosuvastatin
03
Conditions
systolic heart failure (HFrEF)
Beyond the preview
Go deeper on NCT00240292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240292.